PriceTargets.com logo

Medios - MEDOF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$30.00
  • Forecasted Upside: -40.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$50.00 As of 05/12/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for MEDOF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medios Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDOF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDOF

Analyst Price Target is C$30.00
▼ -40.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Medios in the last 3 months. The average price target is C$30.00, with a high forecast of C$30.00 and a low forecast of C$30.00. The average price target represents a -40.00% upside from the last price of C$50.00.

This chart shows the closing price for MEDOF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Medios. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2022Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$50.00 ➝ $30.00
5/7/2021Kepler Capital MarketsReiterated RatingBuy
4/4/2021Jefferies Financial GroupReiterated RatingBuy ➝ Strong-Buy$56.84
3/3/2021Warburg ResearchReiterated RatingBuy
12/8/2020Warburg ResearchReiterated RatingBuy
11/27/2020Jefferies Financial GroupReiterated RatingBuy
11/27/2020Warburg ResearchReiterated RatingBuy
5/20/2020Kepler Capital MarketsReiterated RatingBuy ➝ Average
9/5/2019Berenberg BankReiterated RatingBuy$21.00
(Data available from 9/30/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Medios logo
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. The company was founded in 2016 and is headquartered in Berlin, Germany.
Read More

Today's Range

Now: C$50.00
Low: C$50.00
High: C$50.00

50 Day Range

MA: C$50.00
Low: C$50.00
High: C$50.00

52 Week Range

Now: C$50.00
Low: C$50.00
High: C$50.00

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medios?

The following Wall Street sell-side analysts have issued stock ratings on Medios in the last twelve months: Deutsche Bank Aktiengesellschaft.
View the latest analyst ratings for MEDOF.

What is the current price target for Medios?

1 Wall Street analysts have set twelve-month price targets for Medios in the last year. Their average twelve-month price target is C$30.00, suggesting a possible downside of 40.0%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting MEDOF will reach C$30.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of C$30.00 for Medios in the next year.
View the latest price targets for MEDOF.

What is the current consensus analyst rating for Medios?

Medios currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEDOF will outperform the market and that investors should add to their positions of Medios.
View the latest ratings for MEDOF.

What other companies compete with Medios?

Other companies that are similar to Medios include Alfresa, Arjo AB (publ), Galenica, McKesson Europe and MediPal. Learn More about companies similar to Medios.

How do I contact Medios' investor relations team?

Medios' physical mailing address is Heidestrasse 9, Berlin 10557, Germany. The company's listed phone number is 49 30 232 5668 00. The official website for Medios is www.medios.ag. Learn More about contacing Medios investor relations.